Table 1. SUVmax Cutoff According to Clinicopathologic Features.
| Characteristic | Patients, No. (%) | P value | ||
|---|---|---|---|---|
| SUVmax | All (N = 141) | |||
| ≤5.75 (n = 84) | >5.75 (n = 57) | |||
| Disease stage | ||||
| Localized | 68 (81.0) | 37 (64.9) | 105 (74.5) | .05 |
| Advanced or metastatic | 16 (19.0) | 20 (35.1) | 36 (25.5) | |
| Primary tumor site | ||||
| Digiunum or duodenum | 2 (2.4) | 7 (12.3) | 9 (6.4) | .001 |
| Esophagus | 1 (1.2) | 0 | 1 (0.7) | |
| Ileum | 7 (8.3) | 15 (26.3) | 22 (15.6) | |
| Rectum | 2 (2.4) | 3 (5.3) | 5 (3.5) | |
| Stomach | 72 (85.7) | 31 (54.4) | 103 (73.0) | |
| Extragastrointestinal | 0 | 1 (1.8) | 1 (0.7) | |
| Primary tumor size, cma | ||||
| <5 | 14 (17.3) | 10 (18.9) | 24 (17.9) | .92 |
| >10 | 38 (46.9) | 23 (43.4) | 61 (45.5) | |
| 5-10 | 29 (35.8) | 20 (37.7) | 49 (36.6) | |
| Mitotic index, HPFb | ||||
| ≤5/50 | 37 (61.7) | 10 (26.3) | 47 (48.0) | .001 |
| >5/50 | 23 (38.3) | 28 (73.7) | 51 (52.0) | |
| Classification of riskc | ||||
| Very low | 8 (12.1) | 1 (2.8) | 9 (8.8) | .002 |
| Low | 14 (21.2) | 3 (8.3) | 17 (16.7) | |
| Intermediate | 19 (28.8) | 4 (11.1) | 23 (22.5) | |
| High | 25 (37.9) | 28 (77.8) | 53 (52.0) | |
Abbreviations: HPF, high-power field; SUVmax, maximum standardized uptake value.
a
Three patients were missing for SUVmax of 5.75 or greater and 4 for SUVmax greater than 5.75.
b
Twenty-four patients were missing for SUVmax of 5.75 or greater and 49 for SUVmax greater than 5.75.
c
According to risk-stratification criteria by Miettinen and Lasota.28 Eighteen patients were missing for SUVmax of 5.75 or greater and 21 for SUVmax greater than 5.75.